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Summary
 
Low molecular chemicals (haptens) frequently cause T cell–mediated adverse immune reac-
tions. Our previous work provided evidence that hapten-specific T cells, in analogy to those
specific for nominal peptide antigens, direct their TCR towards hapten-modified, MHC-asso-
ciated peptides. We now demonstrate that trinitrophenyl (TNP)-specific, class I MHC–restricted
CTL from mice may exhibit exquisite specificity for subtle structural details of these hapten de-
terminants, surpassing even the specificity of immunoglobulins. More importantly, these CTL
could be antagonized by ligands altered either in their peptide sequence or in their hapten
structure. The system was employed to examine the molecular basis of T cell antagonism.
Whereas agonists resulted in a dose-dependent downregulation of TCR in different mouse T
cell clones, antagonistic peptides totally failed to do so despite engaging the specific TCR.
Moreover, simultaneous presentation of antagonist and agonist on the same antigen presenting
cell prevented TCR internalization. No signs of anergy or functional receptor inactivation
were observed in CTL treated with antagonist-loaded target cells. Based on a serial triggering
model of T cell activation, our data favor a model in which antagonists block T cell functions
by competitively engaging the specific TCR in unproductive interactions.
 
I
 
n recent years, hapten-reactive T cells have regained
considerable attention reflecting both their involvement
in chemical- or drug-induced allergic disorders as well as
their application in the analysis of general features of TCR-
antigen interactions (1–5). The MHC-restricted contacts
between haptens such as TNP and the corresponding TCR
have been shown to closely reflect those between TCR
and nominal peptide antigens (4–7). T cell–antigenic epi-
topes were found to represent MHC-associated, hapten-
modified peptides and several studies indicate that haptens,
like peptides, may be contacted by the CDR3 loops of the
specific TCR (5, 8). These findings opened a possibility to
examine a novel interaction of T cells with antigen-pre-
senting cells, recently described for T cells directed at nom-
inal peptide antigens. Several groups have reported on the
phenomenon of clonal T cell antagonism (9, 10), demon-
strating that effector functions of these cells can be blocked
by variants of the antigenic peptide. This phenomenon of
theoretical as well as potentially practical importance has
never been studied for T cells directed at hapten-conju-
gated peptides.
The TNP-specific, H-2K
 
b
 
–restricted murine CTL used
for these studies were induced from naive C57BL/6 spleen
lymphocytes with synthetic peptides based on the sequence
of the chicken OVA-derived peptide 257-264 (SIINFEKL,
07) (11) carrying either TNP or DNP substitutions on the
 
e
 
-amino group of Lys 263 (6). The reasons for selecting this
particular carrier peptide were several: (
 
a
 
) peptide 07 binds
with high affinity to the H-2K
 
b
 
 binding groove (11); (
 
b
 
)
the molecular complex of K
 
b
 
 and peptide O7 has been
analyzed by x-ray crystallography (13); (
 
c
 
) CTL reactive to
the unmodified peptide 07 have been extensively studied
with regard to antagonism by mutant peptides (10); and (
 
d
 
)
CTL reacting to K
 
b
 
-associated TNP-peptides modified in
position 7 have been found to contact both the hapten in
position 7 as well as the side chain of amino acid number 4
(6, 14).
Thus, CTL reactive to 07TNP may serve as a readout
system for antagonism by peptides differing from 07TNP
either by amino acid exchanges in position 4 or by altered
hapten substituents in position 7. Our findings demonstrate
that both types of variant ligands, indeed, may result in an
antagonistic blockade of TNP-specific responses. More-
over, we made use of this system to study the downregula-
tion of antigen-specific TCR on mouse cells in response to
agonistic versus antagonistic peptides.
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Materials and Methods
 
Animals and Cells.
 
C57BL/6 mice were provided by the spe-
cific pathogen-free breeding facility at the Max-Planck-Institute
and used at 6–8 wk of age. Previously described cell lines em-
ployed in this study were: RMA and RMA-S T-lymphoma (15),
the TNP-specific CTL clone III/1 (16, 17), the CTL clones 4G3
(18), and B3 (25), both specific for OVA
 
257-264
 
, and the OVA-
transfected EL-4 line E.G7OVA (12).
 
Peptides.
 
Peptides were synthesized as described (17) using
 
e
 
-N-TNP- or 
 
e
 
-N-DNP-lysine modifications (Neosystem, Stras-
bourg, France) to obtain haptenated derivatives. All peptides were
purified by HPLC and purity was confirmed by sequencing and/
or mass spectrometry.
 
Primary In Vitro Induction of CTL.
 
Hapten-peptide specific CTL
were induced in vitro from C57BL/6 spleen cells as previously
described (14). In brief, 4 
 
3
 
 10
 
5
 
 naive spleen cells were coculti-
vated with 3 
 
3
 
 10
 
5
 
 irradiated, syngeneic spleen cells, 1.25 
 
m
 
M pep-
tide, and 7.5% ConA-induced rat spleen supernatant (CASN)
 
1
 
 as
a source of IL-2 in 200-
 
m
 
l cultures in 96-well round bottom
plates (Greiner, Nürtingen, Germany). RPMI 1640 medium was
supplemented with 25 mM Hepes 10% FCS, 2 mM 
 
l
 
-glutamine
and 10 
 
m
 
M 2-mercaptoethanol. Cultures were restimulated and
expanded weekly with fresh stimulators, peptide and CASN. Clones
were generated by limiting dilution and subcloning at 0.3 cells/well.
 
Cytotoxicity Assay.
 
Standard 4 h chromium release assays were
performed as described (17), using 2 
 
3
 
 10
 
3
 
 
 
51
 
Cr-labeled RMA
target cells per well and graded effector/target ratios. Supernatants
from targets in 1 N HCl served as 100% lysis controls, and spon-
taneous Cr release from targets in medium alone was set at 0%.
Targets were pulsed with peptides during the labeling with
 
 
 
51
 
Cr.
For peptide-inhibition assays 
 
51
 
Cr-labeled targets were added to
mixtures of antigenic peptides at suboptimal concentrations with
serial dilutions of inhibitory peptides in a total volume of 150 
 
m
 
l.
After 1 h at 37
 
8
 
C, CTL (4–5 d after restimulation) were added in
50 
 
m
 
l at an effector/target ratio of 3:1. Plates were centrifuged at
40 
 
g
 
, incubated for 4 h at 37
 
8
 
C, and spun again 5 min at 240 
 
g
 
.
Released radioactivity was determined in 100 
 
m
 
l supernatant in a
 
g
 
 radiation counter. All data represent means of triplicates with
SD 
 
,
 
10%.
 
Proliferation Assays.
 
Peptides were mixed in 96-well round-
bottom plates with 3 
 
3
 
 10
 
4
 
 CTL (7–8 d after last stimulation) and
1.2 
 
3
 
 10
 
5
 
 syngeneic, irradiated spleen cells in 200 
 
m
 
l supple-
mented RPMI medium containing 1% CASN. After 48 h, [
 
3
 
H]thy-
midine (0.5 
 
m
 
Ci/well) was added, the cells harvested 14 h later
on GF/A filters, and radioactivity determined in a scintillation-
free 
 
b
 
-counter (Dunn, Asbach, Germany). Peptide inhibition of
T cell proliferation was determined by adding graded amounts of
the peptides to be tested to a fixed but suboptimal concentration
of the antigenic peptide before the addition of CTL and irradi-
ated spleen cells as above.
 
K
 
b
 
-stabilization on RMA-S Cells by Peptides.
 
Stabilization of K
 
b
 
on RMA-S cells was measured as described previously (17, 19).
In short, after 36 h at 26
 
8
 
C 1.2 
 
3
 
 10
 
5
 
 RMA-S cells/well were
mixed with graded concentrations of peptides in 96-well round-
bottom plates, and 30 min later transferred to 37
 
8
 
C. After a 3-h
incubation, cells were washed, labeled with the K
 
b
 
-specific mAb
Y3 (20), and stained with FITC-conjugated goat anti–mouse Ig
(DIANOVA, Hamburg, Germany).
 
FACS
 
Ò
 
 Analysis of TCR Downregulation.
 
RMA cells (1.2 
 
3
 
10
 
5
 
) were mixed in 150 
 
m
 
l RPMI medium in round-bottom mi-
crotiter plates with graded concentrations of the peptides to be as-
sayed, and incubated 1 h at 37
 
8
 
C. CTL, 7–10 d after the last re-
stimulation, were then added at an effector/target ratio of 2:1 in
50 
 
m
 
l. After centrifugation for 5 min at 40 
 
g
 
, and subsequent in-
cubation for 4 h at 37
 
8
 
C, cells were washed twice in 0.5 mM
EDTA/PBS to disrupt conjugates. Cells were labeled either with
mAb 145-2C11 (21), specific for CD3
 
e
 
 or in the case of clone E8
with mAb RR3-16, specific for V
 
a
 
3.2 (22), and stained with
FITC anti-hamster or -mouse Ig, respectively. For flow cytomet-
ric analyses in a FACScan
 
Ò
 
 instrument, RMA cells (negative for
V
 
a
 
3.2) were gated out using FSC/SSC parameters and backgat-
ing on fluorescein-labeled cells. In some experiments the clone
cells were double-stained using a CD8
 
a
 
-specific, PE-labeled an-
tibody (53-6.7; PharMingen, San Diego, CA) and FITC-labeled
V
 
a
 
3.2- or CD3
 
e
 
-specific antibodies (RR3-16 and 145-2C11;
PharMingen).
 
Results
 
Synthetic Peptides and Hapten-specific CTL Clones.
 
The hap-
ten-specific, H-2K
 
b
 
–restricted CTL clones described here
have been obtained by primary in vitro induction of C57BL/6
spleen lymphocytes with synthetic peptides.
Amino acid sequences of all synthetic peptides employed
in these experiments are listed in Table 1 with asterisks in-
dicating the positioning of either DNP or TNP modifica-
tions. As mentioned in the Introduction, all peptides except
for the controls M4L-TNP (17) and VSV (23) were de-
rived from the OVA sequence 257-264 (short name 07)
(11, 24). Three amino acid exchanges were introduced, i.e.,
07(N4R), replacing the position 4 Asp by Arg and
07(N4G) with Gly replacing the Asp. Peptide O4DNP was
derived by exchanging Asp with DNP-modified lysine.
Two of these peptides, i.e., O7TNP and O7(N4G)TNP,
were used to induce K
 
b
 
-restricted CTL. Fig. 1, 
 
A–C
 
 depict
specificities in 
 
51
 
Cr-release assays for one clone induced
with O7TNP (E8) and two clones induced with O7(N4G)
TNP (H12b and G9a). In contrast to earlier findings with
K
 
b
 
-restricted CTL reacting to TNP in position 4 of the
carrier peptides (17), the CTL in Fig. 1 exhibited little or
no cross-reactivity between the haptens DNP and TNP.
 
1
 
Abbreviation used in this paper:
 
 CASN, ConA-induced rat spleen superna-
tant.
 
Table 1.
 
Peptides Used in This Study
 
Short name Sequence
O7 SII
 
N
 
FEK
 
*
 
L
O7(N4R) SII
 
R
 
FEK
 
*
 
L
O7(N4G) SII
 
G
 
FEK
 
*
 
L
O4DNP SIIK
 
*
 
FEKL
M4L-TNP SMQK
 
*
 
FGEL
VSV RGYVYQGL
K
 
b
 
-anchor residues are underlined.
 
*
 
Indicates position of TNP or DNP. 
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The difference of two versus three nitrogroups on the aro-
matic hapten, thus, defined clearly distinguishable determi-
nants for the TCR of clones E8 and H12b. In addition, all
clones were highly sensitive to amino acid changes in posi-
tion 4 of the carrier peptide. Even clone E8, which reacted
to TNP on all three peptide variants (Fig. 1 
 
A
 
), required
significantly different concentrations of these peptides for
half-maximal target sensitization, i.e., 5 nM for the induc-
ing O7TNP, but 500 nM for O7(N4G)TNP or more than
10 
 
m
 
M for O7(N4R)TNP (Fig. 1 
 
D
 
). This demonstrates
the important participation of amino acid position 4 in de-
fining the antigenic epitope detected by CTL directed at
haptens in position 7 of K
 
b
 
-associated peptides.
When antigen-specific proliferation of the three clones
was assayed in presence of the various peptides (Fig. 1, 
 
E–G
 
),
the hapten and carrier specificities were even more pro-
nounced: a significant antigen-specific proliferation was
observed exclusively in the presence of the inducing pep-
tides. In our attempts to examine the effects of hapten- and
peptide sub-epitopes on the quality of TCR contacts we,
therefore, concentrated on the difference between two ver-
sus three nitrogroups in the haptens DNP and TNP, and
on alterations of the side chain of amino acid 4 in the car-
rier peptide.
 
Peptide Binding to H-2K
 
b
 
.
 
Since we aimed at analyzing
the effect of a variant peptide on the effector functions of
CTL clones in the presence of the antigen on the same an-
tigen presenting cell, we had to distinguish between pep-
tide–TCR interaction-related events and mere competition
of these peptides for MHC binding. Therefore, all peptides
were tested for binding to K
 
b
 
. As shown in Fig. 2 
 
A
 
, all
peptides stabilized empty K
 
b
 
-molecules on RMA-S cells at
half-maximal concentrations of 
 
z
 
5 nM. A second test was
based on competitive inhibition of the K
 
b
 
-restricted CTL
clone III/1 (6, 16) that was specific for peptide M4L-TNP,
but did not react to any of the 07-derived peptides. Ad-
mixture of graded concentrations of competitive peptides
to a constant amount of M4L-TNP resulted in dose-
dependent inhibition of target cell lysis by clone III/1. As
shown in Fig. 2 
 
B, again all peptides displayed identical
competitive inhibitory efficacy, strongly suggesting that
neither changes of amino acid 4 nor the modification of
Lys in position 7 with DNP or TNP affected the affinity of
peptide 07 for the Kb-binding groove.
Antagonism by Hapten or Amino Acid Variants of Antigenic
Peptides. Clone E8, induced with and specific for O7TNP,
totally failed to lyse target cells presenting either unmodi-
fied or DNP-conjugated peptides (Fig. 1 A). In contrast to
their completely identical inhibitory activity for clone III/1
(Fig. 2 B), however, Fig. 3 A reveals that the individual
Figure 1. Antigen specificity
of CTL clones. (A–D) Chro-
mium release assays. (A–C) Spe-
cific lysis was determined in the
continuous presence of 1.25 mM
of the indicated peptides (see la-
beling for E–G) as described in
Materials and Methods. CTL-
induced lysis in the absence of
peptides was less than 1%. (D)
Quantitation of antigenicity of
TNP-modified peptides for
clone E8. Antigenic peptides
were titrated into a mixture of
51Cr-labeled RMA targets and
clone E8 at an effector/target ra-
tio of 3:1. (E–G) T cell prolifera-
tion assays. CTL and irradiated
C57BL/6 spleen stimulators
were incubated in the presence
of 1 mM of indicated peptides.
[3H]thymidine incorporation was
determined as described in Ma-
terials and Methods.1806 Hapten Antagonism of T Cells
nonantigenic peptides exhibited substantial differences in
their potential to block specific target cell lysis by clone E8.
Interestingly, the best inhibitor was peptide O7DNP, dif-
fering from the strongest antigen O7TNP exclusively by
the lack of one nitrogroup in the hapten. The hapten-free
peptide O7 and the DNP-derivative O7(N4G) DNP also
showed appreciable inhibition, whereas other peptides such
as O7(N4R) had no effect within the concentration range
tested. Since all peptides possessed comparable affinities for
Kb, such inhibition cannot be accounted for by mere com-
petition and apparently represents an example of peptide-
or hapten-antagonism for a TNP-specific CTL clone.
This argument is supported by inhibitory experiments
with other clones of our collection as well as with the Kb-
restricted clone 4G3, induced against the unmodified pep-
tide 07 in the laboratory of H. Eisen (18). The data in Fig.
3, B and C reveal that clones G9a and H12b, both induced
against 07(N4G)TNP, were best inhibited by 07(N4R)DNP
or 07TNP, respectively, whereas clone 4G3 was most sen-
sitive to peptide 07(N4G) (see Fig. 3 D). Two of these
peptides, i.e., O7(N4G) and O7(N4R)DNP, were com-
paratively poor inhibitors for clone E8 (Fig. 3 A), suggest-
ing that the antagonistic potential of individual peptides re-
lates to their interaction with the respective TCR rather
than with the restricting MHC allele. It is worth mention-
ing that also the agonist-driven proliferation of TNP-spe-
cific clones (Fig. 1, D–F) is inhibited by the respective an-
tagonists (data not shown).
The variation of antagonistic, agonistic, and indifferent
properties of the various peptides in relation to different
CTL clones suggests that even under completely antago-
nizing conditions for one clone, the antigenic determinants
on the same target may still be recognized by other CTL of
corresponding specificities. As an example, admixture of
0.1–1  mM 07(N4R)DNP to 0.07 mM of the agonist 07(N4G)
TNP totally abrogated specific lysis by clone G9a (Fig. 3 B),
but did not at all affect the reactivity of clones E8 or H12b
(Fig. 3, A and C).
In variance with other studies on peptide antagonism for
CD81 T cells (10, 25), in the above cited experiments ago-
nist and potential antagonists were added simultaneously to
the radio-labeled target cells. However, Fig. 4 demonstrates
that the lysis of targets prepulsed with the agonist 07TNP
was also inhibited by subsequent addition of peptides 07DNP
or 07(N4G)DNP, but not of 07(N4R) or 07(N4G) dem-
onstrating that the inhibitory capacity of the peptides is
similar in both assays. The molar excess of inhibitor re-
quired for 50% inhibition in both types of experiments
(10–100-fold) is comparable or even lower than that de-
scribed by Jameson et al. (25) for the antagonistic inhibition
of CTL specific for the unmodified peptide 07.
Monitoring of TNP Determinants on Target Cells. One ad-
vantage of hapten-peptides over nominal peptide antigens
is their visibility for hapten-specific antibodies even when
bound to MHC, i.e., on the surface of target or presenter
cells (17). We made use of this feature to monitor the rela-
Figure 2. Peptide binding to
Kb. (A) Stabilization of Kb on
RMA-S cells at 378C. RMA-S
cells, precultured at 268C, were
treated with the indicated pep-
tides. After 3 h at 378C the cells
were stained with the Kb-specific
mAb Y3 (20) as described in
Materials and Methods. Mean
fluorescence values for RMA-S
cells in the absence of peptide
were 61.5 at 268C and 13.4 at
378C. Control values for the sec-
ond Ab alone were 2.4 at 268C
and 3.6 at 378C. (B) Competitive
lysis inhibition of CTL clone III/1
(6). Clone III/1 is specific for
peptide M4L-TNP (see Table I)
and does not react to any of the
SIINFEKL-derived peptides un-
der investigation (not shown).
Graded concentrations of these
peptides were mixed with 80
nM M4L-TNP and a constant
number of CTL before 51Cr-
labeled targets were added at an
effector:target ratio of 5:1. Spe-
cific lysis was determined as de-
scribed in Materials and Meth-
ods. Lysis in the absence of
competitor peptides was 62% and
background lysis in the absence
of any peptide was below 2%. 1807 Preckel et al.
tive amounts of Kb-associated agonist 07TNP under the in-
fluence of antagonistic or irrelevant Kb-binding peptides.
Fig. 5 A shows TNP-specific staining of RMA-S cells after
incubation with mixtures of a fixed amount of 07TNP and
graded concentrations of the unmodified peptides 07 (an-
tagonistic for clone E8) or 07(N4R) (nonantagonist). Both
peptides reduced TNP expression by 50% at the same con-
centration, again indicating identical affinities for the Kb bind-
ing groove. The less affine VSV peptide required a 100-
fold higher concentration to compete for O7TNP.
In a further experiment (Fig. 5 B) we pulsed RMA-S
cells either with the unmodified peptide O7(N4R) or with
the haptenized O7TNP. After washing, increasing concen-
trations of the respective other peptides were added. As
seen for the circular symbols in Fig. 5 B, no replacement of
Kb-bound TNP-peptide was observed within the time
scale of the experiment (4 h, 378C). The inverse situation,
i.e., pulsing with TNP-free peptide and subsequent titra-
tion of 07TNP (triangular symbols), revealed that despite the
lack of peptide replacement, additional Kb-molecules were
loaded with 07TNP. The extent of this loading was unaf-
fected by the concentration of unmodified peptide in the
prepulse, indicating a binding of 07TNP only to newly ex-
posed empty Kb-molecules.
These data confirm that in our experiments antagonistic
and irrelevant peptides possess an absolutely identical po-
tential to compete for the agonist. In addition, the absolute
number of antigenic determinants on agonist-pulsed target
cells is not decreased upon additional binding of antago-
nists. The inhibitory action of these molecules is, therefore,
likely to involve active interference of antagonist–MHC
complexes with TCR signaling.
TCR Is Engaged by Antagonistic Peptide–MHC Complexes.
To test for a possible engagement of TCR with antagonis-
tic peptide–Kb complexes we employed cold target compe-
tition assays. Nonradioactive (cold) RMA targets loaded
with various peptides were mixed with 51Cr-labeled (hot),
07TNP-pulsed targets and subjected to lysis by clone E8.
As seen in Fig. 6, cold targets presenting either the agonist
07TNP or the antagonist 07DNP resulted in comparative
inhibition of lysis. In contrast, targets pulsed with the irrel-
evant peptide 07(N4R) were indistinguishable from RMA
cells without added peptide. Hence, the antagonistic epitope
clearly interacts with the antagonized TCR. However, this
epitope not only fails to initiate the relevant TCR signals
Figure 3. Clone specific peptide antagonism. Chromium-labeled
RMA targets were mixed with fixed amounts of agonists and graded con-
centrations of the indicated non-antigenic peptides. Agonistic peptides
were O7TNP at 10 nM for clone E8 (A), O7(N4G)TNP at 70 nM for
clones G9a (B) and H12b (C), and O7 at 10 pM for clone 4G3 (D). CTL
of the indicated clones were added at an effector:target ratio of 3:1, and
lysis determined in a 4 h release assay as described in Materials and Meth-
ods. Lysis in the absence of inhibitors was 18% for clone E8, 49% for G9a,
24% for H12b, and 22% for 4G3. Lysis in the absence of agonistic pep-
tides was below 2%.
Figure 4. Antagonism with agonist-pulsed target cells. RMA targets
were pulsed with 100 nM peptide O7TNP (agonist for clone E8) during
the labeling with 51Cr (1.5 h, 378C), washed, and added to graded con-
centrations of the indicated peptides (all non-antigenic for clone E8).
CTL of clone E8 were added at an effector:target ratio of 10:1, and the
assays were performed as described in Materials and Methods. Control
values were 23% in the absence of inhibitory peptides, and below 2% in
the absence of the antigenic peptide O7TNP.1808 Hapten Antagonism of T Cells
for lysis and proliferation, but it even blocks their induction
by TCR–antigen contacts with the correct determinants
presented on the same cell.
Antagonists Block Antigen-induced Downregulation of TCR.
Valitutti and Lanzavecchia have proposed a serial triggering
model for T cell activation in which few agonist–MHC
complexes engage and activate large numbers of TCR (26).
On human CD41 and CD81 T cells, this activation was
shown to culminate in the removal of TCR from the sur-
face of the stimulated cell (27, 28). This model depends on
the assumption that high off-rates between TCR and anti-
gen–MHC complexes result in a minimal, but limited pe-
riod of persistence of these complexes. Antagonists with
supposedly reduced affinity for the TCR (29), were ex-
pected to rapidly inactivate many TCR, thus reducing and
exhausting the pool of receptors available for serial trigger-
ing by agonistic complexes (26). However, this latter prop-
osition has not yet been experimentally tested, nor has the
effect of antigen-specific downregulation of TCR so far
been demonstrated for mouse T cells.
We, therefore, determined TCR expression on the TNP-
specific clones E8, H12b, and G9a. We also analyzed the
Kb-restricted CTL clone B3, induced against the OVA-
peptide SIINFEKL (25). For this clone the peptide O7(N4G)
had been shown to be a potent antagonist (25). T cells
Figure 5. TNP-specific flow
cytometry of Kb-associated
TNP-peptides. (A) Antagonist
and irrelevant peptide compete
identically for binding of
O7TNP to Kb. RMA-S cells
were incubated for 30 min at
268C with mixtures of 50 nM
O7TNP and graded concentra-
tions of the TNP-free peptides
O7, O7(N4R) or VSV. After in-
cubation for 3 h at 378C, cells
were stained with rabbit anti-
TNP serum (44) and FITC-
labeled donkey anti–rabbit Ig
(Dianova, Hamburg, Germany).
Mean fluorescence controls were
2.4 for second Ab alone, 4.7 for
both antibodies in the absence of
TNP-peptide, or 43.7 for
O7TNP in the absence of inhib-
itors. (B) Lack of displacement of
Kb-bound O7TNP. RMA-S
cells were pulsed for 1.5 h at
268C with 2 concentrations of
either O7TNP (circles) or
O7(N4R) (triangles). After exten-
sive washing, graded concentra-
tions of O7(N4R) were added to
the O7TNP-treated cells, and
O7TNP titrated onto the cells
pretreated with O7(N4R). After
3 h at 378C, cells were stained
for TNP as above. Mean fluores-
cence with second Ab alone was
2.5, and staining of untreated
RMA cells resulted in a mean
fluorescence of 4.0.
were coincubated for 4 h with the Kb-expressing RMA
target cells that were either untreated or preloaded with
strong agonists or antagonists. A FACSÒ staining was per-
formed either with anti CD3e mAb or with TCRVa3.2-
specific mAb for clone E8. RMA targets could easily be
gated out according to light scattering properties and did
not require fluorescent labeling. As shown in Fig. 7 A in
original FACSÒ histograms, all 4 clones revealed a signifi-
cant loss of TCR only upon contact with the respective ag-
onists, but not with antagonists. This proves (a) that the
phenomenon of antigen-induced downregulation of TCR
also applies to mouse T cells, and (b) that TCR downregu-
lation occurs in reactions with hapten as well as to nominal
peptide antigens (clone B3).
The dose dependence of the effect was studied in more
detail for the O7TNP-induced clone E8, using the strong
agonist O7TNP, the weaker agonist O7(N4G)TNP, the 2
antagonists O7DNP and O7, or the irrelevant peptide O7
(N4R). As shown in Fig. 7 B, the dose-dependent reduc-
tion of TCR corresponded to the antigenic efficacy of the
two agonistic peptides (Fig. 1 D). In contrast, antagonists
did not induce any measurable loss of surface TCR and
even at high concentration showed values indistinguishable
from those obtained with the irrelevant peptide 07(N4R).
In a further experiment we investigated the effect of an-1809 Preckel et al.
tagonists on the agonist-mediated downregulation of TCR.
Cells of clone E8 were exposed to RMA cells in the pres-
ence of a fixed concentration of the antigen O7TNP,
which resulted in z40% reduction of TCR surface-expres-
sion (Fig. 7 C). Increasing concentrations of the antagonist
07DNP, but not of the irrelevant peptides O7(N4R) and
O7(N4G) gradually inhibited the agonist-induced down-
regulation of TCR. To exclude an unspecific effect of DNP,
peptide O4DNP (Table 1) was included as a further con-
trol. This peptide carries DNP in position 4 and is not
recognized by clone E8, but stabilizes Kb-molecules on
RMA-S cells even slightly better than O7DNP (data not
shown). Also in this case, no inhibition of downregulation
was observed. Moreover, also for a second clone (G9a)
only the antagonist O7(N4R)DNP inhibited the loss of
surface TCR induced by the agonist O7(N4G)TNP. The
irrelevant peptide O7(N4R) had no effect (Fig. 7 D).
Antagonists Fail to Induce Anergy. We also examined whether
CTL, upon contact with antagonists, might be anergized in
terms of a reduction of antigen-specific cytotoxicity or pro-
liferative potential. E8 cells were incubated with BCECF-
AM (29, 7-bis-(carboxyethyl)-5(69)-carboxyfluorescein)-
labeled RMA cells that were either untreated or preincubated
with agonist, antagonist or irrelevant peptide. After a 4-h
incubation the CTL were separated by FACSÒ sorting and
mixed at a defined effector/target ratio with 51Cr-labeled
RMA targets in the presence of titrated amounts of the anti-
gen O7TNP (Fig. 8 A). In parallel we determined the
downregulation of TCR on the CTL cells in these cultures
(Fig. 8 B). The data revealed that, as in the above men-
tioned experiments (Fig. 7), the agonist-contact resulted in
.50% loss of TCR. The reduced receptor density, in turn,
was paralleled by a reduction of cytolytic activity. In con-
trast, preincubation with antagonist-treated target cells had
no effect on TCR-expression as well as on the killing-poten-
tial of the CTL. Contact with antagonist–MHC complexes,
thus, leaves the treated CTL functionally fully active. We
also found (data not shown) the proliferative response of
clone E8 to be unaffected by preincubation with antago-
nist-loaded target cells.
Discussion
The analogy between the activation of T cells by either
nominal peptide antigens or reactive chemicals (haptens)
has been pointed out repeatedly (7, 14). Several laborato-
ries have identified hapten-modified peptides, complexed
to the restricting MHC elements as essential antigenic enti-
ties for hapten-specific T cells (4, 5, 30). The present study
for the first time provides evidence that hapten-reactive T
cells are also subject to antagonism by altered peptide
ligands. The mouse CTL clones under investigation were
induced against H-2Kb–binding octapeptides derived from
the OVA-peptide SIINFEKL (O7), TNP-modified on the
lysine in position 7. The TCR of such clones were previ-
ously shown to contact at least two subepitopes on the an-
tigenic peptides, i.e., the hapten in position 7 and the side
chain of amino acid number 4 (6).
In the present study we provide evidence that alterations
of the amino acid subepitope in position 4 as well as of
the hapten subepitope in position 7 resulted in peptides
with potent antagonistic properties. Thus, removal of one
of the three nitrogroups of the TNP-substituent in peptide
O7TNP, resulting in the corresponding peptide O7DNP,
conferred the strongest agonist for clone E8 into its most
potent antagonist (see Figs. 1 A and 3 A). Antagonism in
this context is understood as an inhibition of the effector
function, i.e., agonist-mediated cytolysis, of a TNP-specific
CTL clone by the simultaneous presence of agonistic and
antagonistic peptides on the same target cell.
This finding has several interesting implications. On one
hand it opens a way to study hapten antagonism in drug al-
lergies. In these cases, e.g., in allergies to b-lactam antibiot-
ics, various degrees of specificity or cross-reactivity be-
tween individual antibiotics have been observed (31), and
numerous structural variations might permit the construc-
tion of potentially antagonistic ligands.
On the other hand, the use of hapten-peptide conjugates
in studies of T cell antagonism has the advantage that these
ligands, in contrast to most nominal peptide antigens, are
detectable by hapten-specific antibodies even in their MHC-
associated state (17). Employing this property we could
show that (a) in our experiments antagonists did not differ
from irrelevant peptides in their efficacy to compete with
the agonist for binding to the Kb binding groove, and (b)
that agonists as well as antagonists, once bound to Kb, could
not be displaced from their binding sites even by addition
of excessive amounts of high-affinity peptides (Fig. 5 B). In
addition, saturation of surface expressed Kb molecules with
external peptides did not prevent the subsequent loading of
Figure 6. Cold target inhibition of TNP-specific lysis by clone E8. Hot
RMA targets (labeled with Na2
51CrO4) were pulsed during labeling with
1 mM agonist O7TNP. Unlabeled (cold) targets were either untreated or
pulsed for 2.5 h with 200 mM of the indicated peptides. Targets were
mixed at a cold/hot ratio of 60:1 (5,000 hot targets per round-bottom
microtiter well), and CTL (clone E8) were added at an effector/hot target
ratio of 3:1. Chromium release was determined as described in Materials
and Methods. Lysis inhibition was calculated from maximal lysis in the
presence of untreated cold targets (52% specific lysis, corresponding to 0%
inhibition). Background lysis of hot targets in the absence of peptides or
cold targets was below 2%. Data represent mean of triplicates with SD in-
dicated.1810 Hapten Antagonism of T Cells
newly expressed Kb molecules with additional peptides on
the same cell (Fig. 5 B). 
The molecular basis of peptide antagonism is still poorly
understood. T cell stimulation with some antagonists has
been demonstrated to result in partial signaling and altered
phosphorylation patterns of TCR associated proteins in
CD41 (9, 32) or CD81 T cells (33). Other authors have
discussed the relationship of antagonism and the induction
of T cell anergy, but could not correlate TCR induced an-
ergy to altered patterns of tyrosine phosphorylation (34).
Although binding constants reported in the literature for
various MHC-agonist-TCR complexes vary considerably
(35–38), some models explain the phenomenon of TCR
antagonism by postulating that defined differences of affin-
ity between antagonist and agonist result in unfavorable ki-
netics for the activation of the T cell (39, 40). In support of
these models, soluble TCR molecules of class I (41) and
class II MHC–restricted T cells (29, 42) were found to bind
with lower affinity to soluble complexes of MHC with an-
tagonistic compared to agonistic peptides.
In this respect, the serial triggering model forwarded by
the group of Lanzavecchia (26, 43) deserves particular in-
terest. This model proposes the activation of large numbers
of TCR by few MHC–agonist complexes, followed by a
Figure 7. TCR downregula-
tion is induced by agonists but
not by antagonists. (A) Va3.2-
specific staining of clone E8,
CD3e-specific staining of clones
B3, H12b, G9a, original FACS
histograms. Clone cells were co-
incubated with RMA cells, ei-
ther untreated or in the presence
of 25 mM antigenic peptides
(O7TNP for clone E8, O7 for
clone B3 and O7(N4G)TNP for
clones H12b and G9a) as de-
scribed in Materials and Meth-
ods. Shown are control stainings
with second Ab only (left open
histogram), stainings after incuba-
tion with untreated or with an-
tagonist treated RMA cells (E8:
O7DNP, B3: O7(N4G), H12b
and G9a: O7(N4R)DNP) (right
open histogram) and stainings after
incubation with RMA cells and
the above mentioned respective
antigenic peptides (shaded histo-
gram). (B) Agonists result in a
dose-dependent downregulation
of TCR. Va3.2-specific staining
of clone E8 as above, but after
coincubation with RMA cells in
the presence of titrated amounts
of the indicated agonistic, antag-
onistic or irrelevant peptides.
Maximal fluorescence for CTL
without or with untreated RMA
cells was 41.2 or 38.9, respec-
tively, and control fluorescence
with second Ab alone was 3.7.
(C and D) Antagonists block ag-
onist-mediated downregulation
of TCR. RMA cells were incu-
bated for 1 h at 378C with graded
concentrations of antagonistic or
irrelevant peptides in the pres-
ence of fixed amounts of agonists
(500 nM O7TNP, C or 1 mM
O7(N4G)TNP, D). After addi-
tion of T cell clones E8 (C) or
G9a (D) and further incubation
for 4 h at 378C the cells were
washed. A double-staining was performed with PE-labeled anti CD8a and FITC-coupled anti-Va3.2- (E8, C) or anti-CD3e-specific antibody (G9a, D).
The TCR-expression was analyzed in the fraction of live, PE-positive cells. RMA cells are negative for CD8a. Mean FITC (TCR) fluorescence in the
absence of peptides (100% control) was 106 for clone E8 (C) and 55 for clone G9a (D). Agonist peptides alone reduced TCR expression to values of 65
(E8, C) or 40 (G9a, D).1811 Preckel et al.
removal of the activated receptors from the cell surface.
The kinetics of this downregulation of TCR is believed to
be controlled by the affinity-dependent persistence of MHC-
peptide-TCR complexes in the contact regions between
APC and T cells. Optimal T cell activation would be char-
acterized by a complete triggering of an optimal threshold
number of TCR, and higher or lower TCR affinities might
result in less efficient or even antagonistic signals. TCR–
antagonist contacts of presumably lower affinity have been
discussed by the authors as possibly resulting in an exhaus-
tion of functional receptors below a critical threshold (26).
However, the activation-related downregulation of TCR
has so far been demonstrated only for human T cells. In
contrast, the effect of T cell antagonists has mostly been in-
vestigated in mouse systems. Our data now demonstrate
that antigen-induced internalization of TCR is also ob-
served for mouse T cells specific for haptenated as well as
for nominal peptide antigens and, hence, represents a gen-
eral phenomenon. Moreover, the extent of downregula-
tion related in a dose-dependent fashion to the antigenicity
of individual TNP-peptides (Fig. 7, A and B). In contrast,
antagonistic peptides were indistinguishable from irrelevant
peptides in failing to induce any downregulation of TCR
(Fig. 7, A and B).
In fact, when added together with the agonist, only an-
tagonists but not irrelevant Kb-binding peptides, blocked
the removal of TCR (Fig. 7, C and D). The fact that no
competition was observed even when irrelevant competi-
tors were added at a 100–1,000-fold excess is reminiscent
of lysis-inhibition data in Fig. 3. This implies that antago-
nists specifically interact with the TCR (also shown by cold
target competition in Fig. 6) and actively inhibit TCR re-
moval from the surface of the T cell. However, antagonists do
not block T cell reactivity via a removal of available TCR.
It remains to be seen whether the process of internaliza-
tion of activated TCR is a necessary part of the signaling
cascade or rather indicates the removal of used receptors
from the system. This leaves at least two possibilities to ex-
plain the action of antagonists: (a) Their interaction with
TCR results in irreversibly wrong phosphorylation patterns
of TCR-associated proteins and a lack of signals for inter-
nalization. The T cell surface would thus be largely occu-
pied by non-reactive, though still antigen-binding, TCR.
(b) The low stability of TCR–antagonist complexes allows
for either no or incomplete phosphorylation, which, by
later contact with the agonist, might in fact be completed.
However, in this case MHC–antagonist complexes due to
their molar excess on the APC as well as to their shorter
contacts with specific TCR (26) might simply compete out
the agonist–MHC complexes on the same APC. A contin-
ual interruption of the serial triggering mechanism either
delaying or preventing a threshold for activation to be
reached would therefore result in reduced T cell activity.
The latter model would, in a way, compare to the cold tar-
get competition experiment (Fig. 6) except that the two
competing structures are located on the surface of the same
target cell.
Our data (Fig. 8) reveal that preincubation of CTL with
antagonist-loaded target cells fails to induce any reduction
of the cytolytic activity or of the proliferative response.
Therefore, we favor a scenario in which on the one
hand, the TCR is not functionally inactivated by the con-
tact with the antagonist while on the other hand, the serial
triggering of many TCR, a prerequisite for full activation
of the T cell, is interrupted.
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Figure 8. Antagonists do not functionally inactivate the TCR. RMA
cells were labeled for 10 min at 378C with 1 mM BCECF-AM (29, 7-bis-
(carboxyethyl)-5(69)-carboxy-fluorescein) (Calbiochem, San Diego, CA)
and washed three times. The labeled cells (1.2 3 105/well) were incu-
bated in 96-well round-bottom plates with 25 mM final concentration of
the indicated peptides (w/o, controls without peptides) for 1 h at 378C be-
fore clone E8 (6 3 104/well) was added. After incubation for 4 h at 378C,
cells were harvested, washed and CTL were separated from fluorescein-
labeled target cells by FACSÒ sorting. After washing, 6,000 sorted CTL
were added to graded concentrations of O7TNP in the presence of 51Cr-
labeled RMA target cells at an effector/target ratio of 3:1. Specific lysis was
determined in a standard chromium-release assay (A). In a parallel experi-
ment, the TCR downregulation of the CTL was measured as for Fig. 7 (B).1812 Hapten Antagonism of T Cells
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